Modern biologic development requires far more than high expression yields or successful purification alone. To advance a therapeutic protein, antibody, recombinant enzyme, vaccine antigen, or other biologic candidate toward preclinical and clinical milestones, organizations must establish a scalable, reproducible, and analytically supported manufacturing process capable of meeting increasingly rigorous quality expectations.
At Profacgen, our Process Development Service is designed to support the complete transition from early-stage molecule evaluation to manufacturing-ready bioprocesses. We integrate upstream process optimization, downstream purification development, analytical characterization, impurity assessment, and IND-enabling development strategies into a coordinated workflow tailored to each product's unique attributes and development goals.
Our scientists work closely with biotechnology companies, pharmaceutical developers, academic laboratories, and industrial partners to establish robust and scalable processes that reduce development risks, improve manufacturability, and support long-term product success.
Whether your project involves recombinant proteins, enzymes, monoclonal antibodies, fusion proteins, cytokines, viral antigens, or other biologics, our team provides scientifically rigorous and commercially relevant process development solutions that bridge discovery and production.
A promising biologic candidate can still encounter major obstacles during scale-up or regulatory preparation if the manufacturing process is not sufficiently optimized. Common development challenges include:
Effective process development addresses these risks early by building a stable and scalable production strategy supported by analytical characterization and quality-focused optimization.
Our integrated approach helps clients:
We provide end-to-end development support across multiple stages of biologics manufacturing and characterization.
| Process | What We Offer |
|---|---|
| Molecule Assessment & Development Planning | Every successful process begins with a thorough understanding of the target molecule and intended application. Our scientists evaluate:
Based on these assessments, we establish a customized development strategy aligned with your project timeline and manufacturing goals. |
| Upstream Process Development | Efficient upstream production is essential for obtaining sufficient product yield while maintaining product quality and process reproducibility. Our upstream development capabilities include:
Small-scale success does not always translate into manufacturing-scale productivity. Our team evaluates process robustness and scalability early in development to minimize future scale-up risks. |
| Downstream Purification Development | Purification strategy plays a critical role in product quality, yield, and manufacturability. We develop purification workflows focused on:
|
Structural & Physicochemical Characterization Support
Comprehensive analytical characterization is essential for understanding product integrity and supporting process decisions.
Our characterization support includes:
These analytical studies help establish product comparability throughout process optimization and scale-up activities.
Impurity & Contaminant Profiling
Residual impurities can significantly impact product quality, safety, and regulatory acceptance.
We provide analytical solutions for detecting and monitoring:
Our impurity profiling strategies help clients improve purification efficiency and establish robust quality control frameworks.
IND-Enabling Process Development Support
As biologics programs advance toward regulatory submission, process development requirements become increasingly rigorous.
Our IND-enabling development support focuses on:
We help clients establish development packages that support smoother transitions into preclinical and clinical manufacturing environments.
Early Discovery Stage
At the discovery stage, we help clients rapidly evaluate manufacturability risks and identify promising development pathways.
Typical activities include:
Preclinical Development
During preclinical development, we focus on improving process robustness and product consistency.
Support areas include:
IND-Enabling Development
For IND-enabling programs, we assist with:
Challenge:
A biotechnology company developing a recombinant cytokine for chronic inflammatory diseases encountered immunogenicity concerns during preclinical development. Accelerated stability studies revealed elevated protein aggregation and particle formation, particularly after freeze-thaw cycles and stressed storage. Significant batch-to-batch variability during purification suggested that upstream processing contributed to structural instability, raising risks for repeated administration and IND-enabling studies.
Solution:
Profacgen implemented an integrated immunogenicity-focused workflow combining structural analysis, formulation optimization, and immune response assessment. SEC-HPLC and dynamic light scattering quantified aggregates across batches. Stress-induced degradation experiments identified aggregation-sensitive variables. Higher-order structure characterization monitored conformational changes via circular dichroism and fluorescence spectroscopy. Multiple buffer systems and excipients were screened to improve stability. PBMC-based cytokine release assays compared immune activation between aggregated and optimized samples.
Outcome:
The assessment identified formulation conditions driving aggregate formation. Buffer optimization reduced aggregate levels and improved stability under accelerated storage. The optimized formulation demonstrated enhanced resistance to freeze-thaw stress and reduced particle generation. PBMC assays showed lower cytokine induction, suggesting reduced immunogenicity risk. The client gained critical insights into aggregation-immunogenicity relationships, strengthening process control and IND readiness.
Challenge:
A biosimilar developer required a robust immunogenicity strategy to support comparative evaluation between a monoclonal antibody biosimilar and its reference product for global regulatory submission. Early feasibility studies revealed inconsistent assay sensitivity across serum matrices and variable drug tolerance depending on assay platform. Glycosylation and impurity differences between the biosimilar and reference product raised concerns regarding assay specificity and cross-reactivity.
Solution:
Profacgen designed a comprehensive immunogenicity assay development workflow. Multiple ligand-binding and electrochemiluminescence platforms were evaluated to balance sensitivity, specificity, and drug tolerance. Comparative ADA screening using both the biosimilar and reference product assessed cross-reactivity. Matrix interference studies optimized sample handling protocols. Drug tolerance assessments were conducted under clinically relevant conditions. Optimized screening, confirmatory, and titer workflows were developed with recommendations for single-assay versus dual-assay strategies.
Outcome:
The optimized framework significantly improved assay reproducibility, sensitivity, and drug tolerance. Matrix interference was substantially reduced, enabling consistent ADA detection across serum backgrounds. Comparative studies demonstrated reliable cross-reactivity, supporting a streamlined immunogenicity strategy. The client gained clarity on how glycosylation, impurities, and assay platform selection influence biosimilar immunogenicity evaluation, providing a robust foundation for regulatory submissions.
Challenge:
A pharmaceutical company scaling up a monoclonal antibody candidate prior to IND-enabling studies observed subtle shifts in glycosylation, charge heterogeneity, and aggregate content compared with research-scale batches. Preliminary stability studies demonstrated increased aggregate formation under stressed conditions in pilot-scale batches, raising concerns that process changes could alter immunogenicity profiles or compromise regulatory comparability.
Solution:
Profacgen implemented an integrated comparability and immunogenicity-focused strategy across manufacturing scales. Glycosylation profiling, charge variant analysis, and SEC-HPLC aggregate assessment characterized physicochemical differences. Stress stability studies evaluated aggregate sensitivity. Cytokine release assays and PBMC-based immune response studies investigated immune activation potential. Comparative impurity analysis assessed residual host cell proteins and process-related contaminants. Critical process parameters were identified to support improved consistency.
Outcome:
Most analytical differences remained within acceptable comparability ranges. Specific upstream feeding conditions contributing to aggregation susceptibility were identified, enabling refined process controls. Cytokine release and PBMC response studies showed no meaningful increase in immune activation potential following optimization. Impurity characterization identified opportunities for improved host cell protein clearance. The resulting analytical framework strengthened IND readiness and supported future manufacturing transition activities.
Fill out this form and one of our experts will respond to you within one business day.